Edition:
United Kingdom

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

4.62USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$4.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
113,297
52-wk High
$6.73
52-wk Low
$1.29

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.66
Market Cap(Mil.): $157.00
Shares Outstanding(Mil.): 37.74
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -0.47 -- --
ROI: -253.29 -7.75 12.60
ROE: -- -10.55 14.49

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

29 Mar 2018

BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019

* GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019

19 Dec 2017

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

05 Dec 2017

UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial

Dec 5 Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

05 Dec 2017

Competitors

Earnings vs. Estimates